Revive Therapeutics Ltd.
5 Director Court, Suite 105
Vaughan
Ontario
L4L 4S5
Canada
Tel: 905-605-5535
Fax: 905-248-3355
Website: http://www.revivethera.com/
149 articles about Revive Therapeutics Ltd.
-
Revive Therapeutics Provides Corporate Update
3/12/2024
Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
-
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
2/1/2024
Revive Therapeutics Ltd. announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.
-
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
1/16/2024
Revive Therapeutics Ltd. announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence.
-
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
1/10/2024
Revive Therapeutics Ltd. is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo.
-
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
12/20/2023
Revive Therapeutics Ltd. is pleased to announce the results of its annual general and special meeting of shareholders held Tuesday, December 19, 2023 in Toronto, Ontario.
-
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
12/18/2023
Revive Therapeutics Ltd. is pleased to announce that it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s next-generation lyophilized formulation of Bucillamine.
-
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development - November 21, 2023
11/21/2023
Revive Therapeutics Ltd. provides an update on the development of a next generation lyophilized formulation of Bucillamine.
-
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
11/6/2023
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) Revive Diagnostics Inc., today announced that it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID.
-
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
10/17/2023
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.
-
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
10/11/2023
Revive Therapeutics Ltd. provides an update on the development of a next generation lyophilized formulation of Bucillamine.
-
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
8/22/2023
Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has initiated the development of a next generation formulation of Bucillamine for the potential treatment of public health medical emergencies including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.
-
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
7/28/2023
Revive Therapeutics Ltd. today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent.”
-
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
7/6/2023
Revive Therapeutics Ltd. announced results of the Company’s Phase 3 clinical trial evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19.
-
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 - May 30, 2023
5/30/2023
Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
5/2/2023
Revive Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board meeting of the Bucillamine Phase 3 clinical trial for COVID-19 is expected to convene on May 10th, 2023 and will assess the efficacy of Bucillamine in the Study’s Post-Dose selection data under the current Study’s protocol primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization.
-
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
3/20/2023
Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19.
-
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
3/8/2023
Revive Therapeutics Ltd. announces today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) to obtain agreement on the proposed protocol endpoints for the Company’s Phase 3 Study (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.
-
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
2/6/2023
PharmAla Biotech Holdings Inc. is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDMA to Revive Therapeutics .
-
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
2/3/2023
Revive Therapeutics Ltd. is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine using PharmaTher’s novel microneedle patch delivery technology.
-
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
1/19/2023
Revive Therapeutics Ltd. announces today that it has submitted the updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include the rationale for the proposed primary and efficacy endpoints for the amended protocol in the treatment of COVID-19 and supporting new information and independent published studies, including the most recent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction.”